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Obesity is recognized as a state of chronic low-grade 
inflammation and associated with type-2 diabetes, 
dyslipidemia, nonalcoholic fatty liver disease, 
atherosclerosis, hypertension and acute myocardial 
infarction [1-3]. Obesity-induced inflammation appears 
to occur mainly in insulin-sensitive tissues (e.g., adipose 
tissue, liver and muscle) in obese humans, especially 
those with symptomatic metabolic disorders [4]. As for 
the proinflammatory mediators, previous studies 
detected enormous numbers of proinflammatory macro-
phages and neutrophils  in  adipose  and  hepatic  tissues 
 
from animal models and obese patients [5]. 
Macrophages are well-known to undergo classical M1 
polarization or alternative M2 polarization. M1 
macrophages secrete pro-inflammatory cytokines such 
as  interleukin-6 (IL-6), tumor necrosis factor-α (TNF-
α), interleukin-1β (IL-1β) [4]. Adipose tissue inflam-
mation mainly stimulates M1 macrophage polarization 
and even induces the phenotypic switch from M2 to M1 
macrophages [6]. M1 macrophages release the pro-
inflammatory cytokines to exacerbate inflammation in 
adipose tissues and promote insulin resistance in obesity 
[7, 8]. On the other hand, obesity drives adipose tissues 
to undergo pathological expansion, thereby creating 






















Macrophage polarization  is  implicated  in  the  inflammation  in obesity.  The  aim of  the present  study was  to
examine  the  anti‐inflammatory  activities  of  botanical  triterpene  celastrol  against  diet‐induced  obesity. We
treated diet‐induced obese C57BL/6N male mice with celastrol (5, 7.5 mg/kg/d) for 3 weeks, and  investigated
macrophage  M1/M2  polarization  in  adipose  and  hepatic  tissues.  Celastrol  reduced  fat  accumulation  and
ameliorated glucose tolerance and insulin sensitivity. Celastrol down‐regulated the mRNA levels of macrophage
M1 biomarkers  (e.g.,  IL‐6,  IL‐1β,  TNF‐α,  iNOS)  in  cell  culture  and  in mice.  The underlying mechanisms were
investigated  in murine macrophage  RAW264.7  cells. Our  results  demonstrated  that  celastrol might  control
macrophage  polarization  through  modulating  the  cross‐talk  between  the  following  three  mechanisms:  1)
suppressing  LPS‐induced  activation  of MAP  kinases  (e.g.,  ERK1/2,  p38,  JNK)  in  a  concentration  dependent
manner; 2) attenuating LPS‐induced nuclear translocation of NF‐κB p65 subunit in a time dependent manner; 3)
activating  Nrf2  and  subsequently  inducing  HO‐1  expression.  HO‐1  inhibitor  SnPP  diminished  the  inhibitory
effects of celastrol on the activation of NF‐κB pathway and the pro‐inflammatory M1 macrophage polarization.
Taken  together,  celastrol  exhibited  anti‐obesity  effects  via  suppressing  pro‐inflammatory  M1  macrophage
polarization. Thus, our results provide new evidence for the potential of celastrol in the treatment of obesity. 
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hypoxic microenvironment [9]. A recent study found 
that hypoxia affected ~1,300 genes including leptin, 
adiponectin, IL-1β and IL-6 [10]. Pro-inflammatory 
cytokines synergistically alter the cell-cell communica-
tions between macrophages, preadipocytes and 
adipocytes, causing insulin resistance and type-2 
diabetes [8, 11]. Interestingly, M1 macrophages may 
communicate with the remote cells via several pro-
inflammatory cytokines, for example, colonic M1 
macrophages cause inflammation and insulin resistance 
in “remote” adipose tissues [12]. It was previously 
underestimated that hepatic macrophages could directly 
cause insulin resistance. Liver is densely populated with 
resident macrophages, also known as Kupffer cells [13]. 
M1 macrophages may also promote inflammation in 
adipose and hepatic tissues. For the exact mechanisms 
by which hepatic macrophages cause insulin resistance 
in liver, pro-inflammatory cytokines and free fatty acids 
are well-known to induce the over-activation of c-JUN 
N-terminal kinase (JNK), leading to the insulin 
resistance and diabetes [14]. Along this line, M1 
macrophages could promote insulin resistance via 
activating JNK and nuclear factor-kappa B (NF-κB) 
pathways. Indeed, JNK and NF-κB pathways are often 
activated in multiple tissues and thereby mediate tissue 
inflammation in obesity. On the other hand, M2 
macrophages overexpress anti-inflammatory factors 
such as interleukin-10 (IL-10) and arginase-1to 
ameliorate insulin resistance in obesity [6, 15]. M2 
Kupffer cells ameliorated insulin resistance and delayed 
the progression of obesity-induced steatohepatitis in 
mice [16]. Therefore, we postulate that macrophage 
polarization should be timely reprogrammed towards an 
anti-inflammatory M2 phenotype for resolution of 
inflammation in obesity. 
 
Triterpene celastrol was initially identified from the 
plant Tripterygium wilfordii for its anti-oxidant, anti-
inflammatory, anti-cancer and anti-rheumatoid arthritis 
activities [17, 18]. Celastrol was recently identified 
from more than 1000 small molecules as the best hit for 
treating diet-induced obesity [19]. It was found that 
celastrol might enhance leptin activity for suppressing 
appetite and inducing weight loss [19, 20]. Indeed, the 
pathological disruption of the leptin-adiponectin axis 
contributed to increased systemic inflammation and 
oxidative stress in patients with the metabolic syndrome 
(MS) [21]. However, celastrol may elicit anti-obesity 
activities by several other mechanisms. One earlier 
study showed that celastrol increased antioxidant 
capacity and improved lipid metabolism in diet-induced 
obesity [22]. Another recent study demonstrated that 
celastrol improved obesity and metabolic dysfunctions 
through activating heat shock factor (HSF)-PGC1α 
transcriptional axis [23]. Presumably, celastrol could 
regulate the anti-inflammatory activity, leptin activity 
and food intake in a coordinated manner. Nevertheless, 
it remains elusive whether celastrol fights obesity-
induced inflammation through skewing macrophage 
polarization from proinflammatory M1 to anti-
inflammatory M2.  
 
In the present study, we treated diet-induced obese mice 
with celastrol for three weeks and confirmed the effects 
of celastrol on fat accumulation, glucose tolerance and 
insulin sensitivity. We hypothesized that celastrol might 
promote weight loss in diet-induced obese mice via 
attenuating inflammation. Thereby, we examined not 
only the effects of celastrol on the expression of 
proinflammatory biomarkers in adipose tissue and liver 
but also the activation of inflammation-related signaling 
pathways including MAP kinases, NF-κB, nuclear 
factor erythroid-2-related factor/heme oxygenase-1 
(Nrf2/HO-1) pathways in macrophages. In addition, we 
explored whether celastrol could skew macrophage 
polarization from proinflammatory M1 toward anti-




Celastrol promoted weight loss and glucose 
homeostasis 
 
To examine the potential of celastrol to treat diet-
induced weight gain, we firstly generate a mouse model 
of over-weight by feeding mice with 60 kcal % high fat 
diet (HFD) over three months. We subsequently divided 
the obese mice into three treatment groups: HFD, on 
HFD only; HFD+C5, on HFD supplemented with 5 
mg/kg/d celastrol; and HFD+C7.5, on HFD supplement-
ed with 7.5 mg/kg/d celastrol. Celastrol treatment was 
continued for another three weeks while the wellness 
and body weight of mice were monitored on daily basis. 
No signs of intoxication were detected in behavioral 
assessment and hematoxylin and eosin (H&E) staining 
of major organs (data not shown). As shown in Fig. 1A, 
celastrol at the doses of 5 and 7.5 mg/kg/d effectively 
promoted weight loss to the control levels after two 
weeks although the animals were still on HFD. Mice in 
HFD group did not gain body weight during the 
treatment period. Fat mass was visually examined and 
accurately determined by NMR technology at the end of 
celastrol treatment. As shown in Fig. 1B, celastrol 
reduced fat accumulation in HFD mice in a dose-
dependent manner (n = 10, p < 0.001). Especially, 
celastrol at the dose of 7.5 mg/kg/d recover the fat 
contents in HFD mice to the similar level in control 
mice. To further determine the effects of celastrol on 
glucose tolerance and insulin sensitivity, we conducted 
two common experimentrs, intra-peritoneal glucose 
tolerance test (ipGTT) and insulin tolerance test (ITT), 
respectively. As shown in Fig. 1C and 1D, mice in HFD 
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group evidently showed aberrantly high blood glucose 
level, known as prediabetic state. Interestingly, HFD 
mice treated with celastrol at the doses of 5 and 7.5 
mg/kg/d effectively consumed blood glucose to the 
similar level in control mice (n = 6, p < 0.001). 


















































tive to exogenous insulin and maintained high blood 
glucose level. Celastrol at the doses of 5 and 7.5 
mg/kg/d effectively improved insulin sensitivity in HFD 
mice (n = 6, p < 0.001). Celastrol-treated and control 
mice exhibited similar blood glucose level in response 




















































Figure 1. Celastrol attenuated diet‐induced obesity  in C57BL/6N mice. (A) Celastrol promoted weight  loss. Diet‐
induced obese mice were treated with celastrol (0, 5, 7.5 mg/kg/d) for 21 days, whereas control mice were fed with normal
diet. Body weight was daily measured. (B) NMR determination of fat contents. After 21‐day treatment, fat contents in mice
were  analyzed  by  Bruker minispec NMR  analyzer.  (C) Glucose  tolerance  test  (GTT).  After  glucose  injection,  blood was
collected and analyzed for glucose  level. The area under curve (AUC) for each group was calculated. (D)  Insulin tolerance
test (ITT). After insulin injection, blood was collected and analyzed for glucose level. The AUC for each group was calculated.





















































































































adipose  tissues  and  liver.  (A)  Detection  of  iNOS,  COX‐2,  and  arginase‐1  in  epididymal  adipose  tissues.  After  21‐day
treatment,  epididymal  fat pads were  recovered  from mice,  and  stained with  specific  antibodies. CD68 was  stained  as pan‐
macrophage  biomarker whereas  the  cell  nuclei were  stained with DAPI.  The  sections were  imaged  under  a  Zeiss  LSM  780
confocal microscopy. Representative images were shown. Scale bar, 50 μm. (B) qRT‐PCR quantification of macrophage M1 and
M2  biomarkers  in  epididymal  adipose  tissues.  Total  RNAs were  extracted  from  adipose  tissues  and  analyzed  by  qRT‐PCR
technique using QuantiTect SYBR Green PCR Kit and specific DNA primers from Qiagen. N = 3; HFD, HFD only; C7.5, celastrol (7.5
mg/kg/d).  (C) Detection of  iNOS, COX‐2,  and  arginase‐1  in  liver  tissues.  Livers were  recovered  from mice,  and  stained with
specific  antibodies.  CD68 was  stained  as  pan‐macrophage  biomarker whereas  the  cell  nuclei were  stained with DAPI.  The
sections were  imaged under a Zeiss LSM 780 confocal microscopy. Representative  images were shown. Scale bar, 50 μm. (D)
qRT‐PCR  quantification  of macrophage M1  and M2  biomarkers  in  liver  tissues.  Total  RNAs were  extracted  from  livers  and
analyzed by qRT‐PCR technique using QuantiTect SYBR Green PCR Kit and specific DNA primers from Qiagen company. N = 3;
HFD, HFD only; C5, celastrol (5 mg/kg/d); C7.5, celastrol (7.5 mg/kg/d); *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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Celastrol reduced the plasma levels of IL-6 and IL-
1β in mice 
 
To evaluate the in vivo effects of celastrol on the release 
of pro-inflammation cytokines, mouse plasma was 
collected from mice in four treatment groups (i.e., 
Control, HFD, HFD+C5, HFD+C7.5). The plasma 
levels of IL-6, TNF-α and IL-1β were determined by 
enzyme-linked immunosorbent assay (ELISA) kits. As 
shown in Fig. 1E and 1F, HFD increased the plasma 
levels of IL-6 and IL-1β while celastrol effectively 
reduced the plasma levels of IL-6 and IL-1β to the 
normal levels in a dose-dependent manner. No signals 
were detected for TNF-α in mouse plasma. 
 
Celastrol suppressed pro-inflammatory macrophage 
M1 polarization and slightly enhanced macrophage 
M2 polarization in adipose tissue and liver 
 
To determine the in vivo effects of celastrol on 
macrophage polarization, mouse epididymal fat pads 
and livers were recovered from animals in three 
treatment groups (i.e., Control, HFD, HFD+C7.5), and 
subsequently examined the expression of the typical 
biomarkers for inflammation and macrophage 
polarization by immunostaining and qRT-PCR techni-
ques. For adipose tissues, as shown in Fig. 2A, 
epididymal fat pads were stained with antibodies 
against inducible nitric oxide synthase (iNOS), 
cyclooxygenase-2 (COX-2) and arginase-1, whereas 
CD68 was stained as a pan macrophage biomarker, and 
DAPI as a probe for cell nuclei. HFD increased the 
expression of iNOS and COX-2 in macrophages, while 
celastrol selectively reduced the expression of iNOS 
over COX-2. Interestingly, celastrol somehow enhanced 
the expression of arginase-1 in macrophages. To further 
examine the effects of celastrol on macrophage M1/M2 
polarization in adipose tissues, we determined the 
expression levels of the typical macrophage biomarkers 
by qRT-PCR. As shown in Fig. 2B, HFD elevated the 
mRNA levels of several pro-inflammatory biomarkers, 
whereas celastrol diminished the mRNA expression of 
pro-inflammatory genes including IL-6, IL-1β, TNF-α 
and iNOS, and also marginally increased the mRNA 
level of IL-10 over arginase-1. On the other hand, 
hepatic tissues were stained with antibodies against 
iNOS, COX-2 and arginase-1, whereas hepatic macro-
phages were stained with anti-CD68 antibody and the 
cell nuclei were stained with DAPI. As shown in Fig. 
2C, HFD increased the expression of iNOS and COX-2 
in hepatic macrophages, whereas celastrol treatment 
selectively reduced iNOS expression over COX-2. 
Interestingly, celastrol enhanced arginase-1 expression 
in hepatic macrophages. Furthermore, the expression of 
inflammation and macrophage biomarkers was 
determined by qRT-PCR technique. As shown in Fig. 
2D, qRT-PCR revealed that HFD generally increased 
the mRNA expression of selected biomarkers for 
inflammation and macrophage polarization. However, 
celastrol at the dose of 7.5 mg/kg/d effectively reduced 
the mRNA expression of pro-inflammatory genes 
including IL-6, IL-1β, TNF-α and iNOS back to the 
normal levels or even lower levels, while upregulated 
the expression level of arginase-1 mRNA and to a lesser 
extent, IL-10 mRNA.  
 
Celastrol suppressed proinflammatory M1 
macrophage polarization in murine macrophage 
RAW264.7 cells  
 
To clarify whether celastrol targets macrophages, we 
examined the effects of celastrol on the expression of 
selected biomarkers in mouse macrophage cell line 
RAW264.7. We firstly evaluated the effect of celastrol 
on the cell viability in RAW264.7 cells over a period of 
48 h. As shown in Fig. 3A, celastrol could exhibit 
detectable cytotoxicity when the concentration was 
raised up to 1.25 μM (p < 0.01). Celastrol eventually 
exhibited the IC50 value of 1.69 μM against the growth 
of RAW264.7 cells. We thereby treated RAW264.7 
cells with celastrol at the concentrations below 1.25 μM 
for other experiments. We subsequently investigated the 
effects of celastrol on the expression of iNOS, COX-2 
and arginase-1 by Western blot analysis. RAW264.7 
cells were pre-treated with celastrol for 1 h and 
challenged with LPS for another 24 h. As shown in Fig. 
3B, celastrol remarkably attenuated LPS-induced iNOS 
expression (p < 0.001), effectively up-regulated 
arginase-1 expression (p < 0.01) in a concentration-
dependent manner. Unexpectedly, celastrol appeared to 
potentiate LPS-induced COX-2 expression. We further 
investigated the effects of celastrol on the mRNA 
expression of several key pro-inflammatory M1 and 
anti-inflammatory M2 biomarkers by qRT-PCR 
technique. As shown in Fig. 3C, LPS profoundly up-
regulated six common M1 macrophage biomarkers 
while showed less effects on the expression of M2 
macrophage biomarkers arginase-1 and IL-10. Celastrol 
not only suppressed LPS-induced expression of M1 
macrophage biomarkers including IL-6, IL-1β, iNOS, 
TNF-α, CCL2 and CXCL-10 in a concentration-
dependent manner, but also upregulated the mRNA 
expression of M2 macrophage biomarkers arginase-1 
and IL-10 (p < 0.05) when the concentration was raised 
to 0.75 μM.  
 
Celastrol attenuated LPS-induced activation of MAP 
kinases in macrophages  
 
To elucidate the mechanisms by which celastrol 
regulates macrophage polarization, we firstly examined 
the effects of celastrol on LPS-induced activation of 
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MAP kinases in RAW264.7 cells. We pretreated the 
cells with celastrol at the concentrations of 0.25, 0.5 and 
0.75 μM for 1 h and challenged with LPS for another 24 
h. The activation of MAP kinases was examined by 
Western blot analysis. As shown in Fig. 4A, LPS (1 
μg/mL) dramatically activated the phosphorylation of 
p38, extracellular signal-regulated kinase (ERK1/2) and 
JNK. Celastrol effectively attenuated LPS-induced 
phosphorylation of p38, ERK1/2 and JNK in a 
concentration-dependent manner.  
 
Celastrol inhibited LPS-induced nuclear 
translocation of NF-κB p65 but activated Nrf2/HO-1 
pathway 
 
To further investigate the effects of celastrol on pro-
inflammatory NF-κB pathway and antioxidant 
Nrf2/HO-1 pathway, we focused on the nuclear 
translocation of transcriptional factors NF-κB p65 
subunit and Nrf2 and the induction of anti-oxidant 
enzyme HO-1. For the nuclear translocation of NF-κB 


































for 1 h and subsequently challenged the cells with LPS 
for another 3, 6 or 12 h. Nuclear and cytoplasmic 
proteins were prepared and analyzed by Western blot 
analysis. As shown in Fig. 4B, LPS profoundly 
increased the presence of NF-κB p65 subunit in the 
nuclear fractions. Cleastrol effectively attenuated the 
stimulatory effects of LPS on the nuclear translocation 
of NF-κB p65 subunit and promoted the sequestration 
of NF-κB p65 subunit in the cytosol in a time-
dependent manner. On the other hand, for the nuclear 
translocation of Nrf2, we treated the cells with 0.25, 0.5, 
0.75 and 1 μM celastrol for 3 or 6 h. Nuclear and 
cytoplasmic proteins were similarly prepared and 
analyzed by Western blot analysis. As shown in Fig. 
4C, celastrol effectively induced the nuclear 
translocation of Nrf2 in a concentration- and time-
dependent manner. Furthermore, we treated the cells 
with celastrol for 24 h and examined the expression 
levels of Nrf2-target gene HO-1 by Western blot 
analysis. As shown in Fig. 4D, celastrol indeed 








































by Western blotting with specific antibodies and GAPDH  (as  loading control). The blots  (n = 3) were quantified by a densitometric























































































































in  combination  with  celastrol,  the  cellular  proteins  were  analyzed  by  Western  blotting  with  specific  antibodies.
Representative blots were shown. The blots (n = 3) were quantified by a densitometric method. C0.25, celastrol (0.25 μM);
C0.5,  celastrol  (0.5  μM); C0.75,  celastrol  (0.75  μM);  **, p  <  0.01;  ***, p  <  0.001.  (B) Nuclear  translocation  of NF‐κB p65
subunit. After treatment with 1 μg/ml LPS alone or in combination with 1 μM celastrol, the nuclear and cytoplasmic proteins
were prepared and analyzed by Western blotting with specific antibodies. Lamin B and GAPDH were used as loading control.
Representative  blots  were  shown.  (C)  Nuclear  translocation  of  Nrf2.  After  treatment  with  celastrol,  the  nuclear  and
cytoplasmic proteins were prepared and analyzed by Western blotting with  specific antibodies. Lamin B and GAPDH were
used  as  loading  control.  Representative  blots were  shown.  (D)  Induction  of HO‐1  expression.  After  24  h  treatment with
celastrol,  the cellular proteins were analyzed by Western blotting with specific antibodies and GAPDH  (as  loading control).
Representative blots were shown. The blots (n = 3) were quantified by a densitometric method. *, p < 0.05; ***, p < 0.001. 
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Celastrol suppressed macrophage M1 polarization 
via Nrf2/HO-1-mediated mechanism 
 
To clarify whether celatrol stimulates the phenotypic 
switch of macrophages via inducing HO-1 expression, 
we conducted three different experiments to examine 

















































dichloride (SnPP) on the nuclear translocation of NF-κB 
p65 subunit, expression of iNOS and COX-2, and 
expression of macrophage biomarkers. For Experiment 
1, we treated RAW264.7 cells with LPS, celastrol and 
specific HO-1 inhibitor SnPP, alone or in combination, 
for 6 h. We subsequently detected the intracellular 
























































were  quantified  by  a  densitometric method.  Representative  blots were  shown.  ***,  p  <  0.001.  (C)  Attenuation  of  celastrol
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cence staining. As shown in Fig. 5A, HO-1 inhibitor 
SnPP effectively abolished the inhibitory effect of 
celastrol on LPS-induced nuclear translocation of NF-
κB p65 subunit. For Experiment 2, we treated 
RAW264.7 cells with LPS, celastrol and specific HO-1 
inhibitor SnPP, alone or in combination, for 24 h. The 
protein levels of iNOS and COX-2 were analyzed by 
Western blotting. As shown in Fig. 5B, celastrol 
attenuated LPS-induced iNOS expression, whereas HO-
1 inhibitor SnPP eventually abolished the activity of 
celastrol against LPS-induced iNOS expression. Neither 
of celastrol and SnPP affected COX-2 expression in 
LPS-stimulated macrophages. For Experiment 3, we 
treated RAW264.7 cells with LPS, celastrol and specific 
HO-1 inhibitor SnPP, alone or in combination, for 24 h. 
We determined the effects of HO-1 inhibitor on the 
mRNA levels of macrophage M1 and M2 biomarkers 
relative to LPS and celastrol. As shown in Fig. 5C, HO-
1 inhibitor SnPP diminished the activities of celastrol 
against LPS-induced mRNA expression of the pro-
inflammatory M1 biomarkers (e.g., IL-6, IL-1β, iNOS 
and TNF-α) and the anti-inflammatory M2 biomarkers 




Macrophage phenotypes are associated with adipose 
tissue inflammation, metabolic disorders and insulin 
resistance in obesity [24, 25]. Inflammatory M1 
macrophages cause adipose tissue inflammation and 
insulin resistance, whereas anti-inflammatory M2 
macrophages ameliorate obesity-induced insulin resis-
tance [26]. The aim of the present study was to examine 
whether plant-derived celastrol could promote weight 
loss and attenuate inflammation in diet-induced obese 
mice via suppressing macrophage M1 polarization 
while stimulating macrophage M2 polarization. We 
confirmed that celastrol not only effectively promoted 
weight loss but also improved glucose tolerance and 
insulin sensitivity. In the present study, we focused on 
the effects of celastrol on the expression of macrophage 
polarization biomarkers and the underlying 
mechanisms. 
 
Celastrol was proven to be effective in the control of 
weight gain and blood glucose levels in mouse and rats 
models of high fat-induced obesity [19, 22]. As far as 
the drug safety is concerned, celastrol did not cause 
evident toxic effect in wild-type mice after i.p. adminis-
tration of 100 μg/kg/d for 195 and 216 days [19]. In the 
present study, we firstly validated the effects of 
celastrol on weight gain in obese mice (Fig. 1A-B). 
Although celastrol was administered at the dose of up to 
7.5 mg/kg/d by oral gavage, no sign of toxicity was 
observed. Consistently, it was previously demonstrated 
that celastrol at the dose of 10 mg/kg/d did not cause 
weight loss in lean mice over three weeks of treatment 
[19]. By examining the effects of celastrol on glucose 
tolerance and insulin insensitivity, we found that 
celastrol could ameliorate obesity-disrupted glucose 
homeostasis and insulin resistance (Fig. 1C-D). As far 
as the pathology of obesity, low-grade chronic 
inflammation is a direct cause for insulin resistance and 
metabolic dysfunctions in adipose tissues [7]. The 
inflamed adipose tissues secrete various inflammatory 
signals to recruit macrophages. Adipose tissue 
infiltrating macrophages were proinflammatory and 
exhibited classically activated M1 phenotype [27]. 
Based on the previous study on the tissue distribution of 
celastrol [28], after i.p. administration of 4 mg/kg for a 
period of 240 min, the prolonged and steady levels of 
celastrol were detected in liver but not in other organs 
from KM mice. In the present study, therefore, we 
focused on the effects of celastrol on macrophage 
M1/M2 polarization in livers and adipose tissues. We 
employed Western blotting, qRT-PCR and fluorescence 
immunostaining to determine the expression levels of 
typical macrophage M1 and M2 biomarkers. By 
examining the adipose tissues and livers from the 
experimental mice, we found more M1 macrophages in 
mice on high fat diet, while M2 macrophages in mice 
on high fat diet supplemented with celastrol. Moreover, 
celastrol at the dose of 7.5 mg/kg/d decreased the 
expression of pro-inflammatory M1 biomarkers while 
increased the expression of macrophage M2 biomarkers 
(e.g., arginase-1 and IL-10) in adipose tissues and livers 
(Fig. 2). In addition, we also found that celastrol 
decreased the plasma levels of IL-6 and IL-1β in HFD-
fed mice (Fig. 1E-F), which was consistent with the 
previous findings [29]. Taken together, our results 
suggested that celastrol suppressed macrophage M1 
polarization, but somewhat enhanced macrophage M2 
polarization against in vivo inflammation in adipose 
tissues and livers.  
 
MAP kinases (e.g., ERK1/2, JNK and p38) and NF-κB 
signaling pathway are implicated in obesity-induced 
type-2 diabetes and insulin resistance [30]. It was found 
that MAP kinases and NF-κB pathway were activated in 
multiple tissues in obesity, possibly promoting tissue 
inflammation [31]. Other studies discovered that pro-
inflammatory cytokines and free fatty acids caused the 
over-activation of JNK, leading to the insulin resistance 
and diabetes [14]. Along this line, celastrol was 
previously demonstrated to inhibit the activation of 
MAP kinases and NF-κB pathway, and thereby decrease 
the release of inflammatory cytokines [32]. Moreover, 
high-fat meal increased circulating LPS levels in type 2 
diabetic patients [33]. Animal studies showed that HFD 
enhanced circulating LPS levels through altering 
intestinal permeability [27]. The same study also 
demonstrated that subcutaneous infusion of LPS could 
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initiate obesity and insulin resistance. In the present, 
therefore, LPS was used to activate macrophage 
RAW264.7 cells. Indeed, we found that LPS increased 
the expression of a bunch of pro-inflammatory M1 
macrophage biomarkers. Interestingly, our results 
revealed that celastrol down-regulated the mRNA and 
protein levels of LPS-induced M1 biomarkers (e.g., IL-
6, IL-1β, iNOS and TNF-α) while enhanced the mRNA 
and protein levels of anti-inflammatory M2 markers 
(e.g., arginase-1 and IL-10) in a concentration-
dependent manner (Fig. 3). Moreover, the present study 
demonstrated that celastrol antagonized LPS activity to 
activate MAP kinases and NF-κB pathway (Fig. 4A-B). 
In addition, a recent study showed that celastrol could 
induce HO-1 expression through reactive oxygen 
species (ROS)/Nrf2/ARE mechanisms [34]. In the 
present study, we firstly confirmed that celastrol 
stimulated the nuclear translocation of Nrf2 and induced 
HO-1 expression in a concentration dependent manner 
(Fig. 4C-D). We subsequently clarified that HO-1 
inhibitor SnPP could largely diminish the inhibitory 
effects of celastrol on LPS-induced activation of NF-κB 
pathway and the synthesis of macrophage M1 and M2 
biomarkers by immunofluorescence staining, western 
blot analysis and qRT-PCR technique (Fig.5A-C). 
Collectively our results suggested that celastrol might 
suppress macrophage M1 polarization against inflam-
mation through two related mechanisms: direct 
induction of HO-1 expression through inhibiting the 
activation of MAP kinases and NF-κB pathway and 
activating Nrf2/HO-1 pathway (Fig. 5D). 
 
In summary, the present study validated that celastrol 
not only promoted the weight loss but also ameliorated 
glucose tolerance and insulin insensitivity in diet-
induced obese mice. The key finding was that the anti-
inflammatory and anti-obesity activities of celastrol 
may be linked by promoting macrophage polarization 
from M1 to M2 phenotype. Such information warrants 
further investigations on the potential roles of macro-
phage polarization in hepatic and adipose tissues in the 
regulation of leptin activity and appetize in the brain. 
Nevertheless, our results support the development of 
celastrol as a promising drug candidate for treating 
obesity.  
 
MATERIALS AND METHODS 
 
Antibodies and biochemical reagents 
 
Antibodies against p38, ERK1/2, JNK, GAPDH, Lamin 
B, phospho-p38, phospho-ERK1/2, phospho-JNK, 
COX-2 were purchased from Cell Signaling 
Technology (Boston, MA, USA). Antibodies against 
arginase-1, HO-1, Nrf2 and NF-κB p65 were purchased 
from Santa Cruz Biotechnology (Dallas, TX, USA). 
Antibodies against iNOS and CD68 were purchased 
from Abcam (Cambridge, UK). Anti-rabbit HRP-
conjugated IgG secondary antibody and 
lipopolysaccharide (LPS) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Dulbecco’s modified 
Eagle’s Medium (DMEM), fetal bovine serum (FBS) 
and 100x penicillin and streptomycin solution were 
purchased from Invitrogen (Carlsbad, CA, USA). 
Protein assay dye reagent concentrate was purchased 
from Bio-Rad (Hercules, CA, USA). HO-1 inhibitor 
SnPP was purchased from Frontier Scientific Inc 
(Logan, UT, USA). Celastrol with the purity of over 
98% by HPLC was purchased from Nanjing Spring and 
Autumn Biological Engineering Co., Ltd. (Nanjing, 
China). 
 
Mouse husbandry and drug treatment  
 
Protocols for animal experiments were approved by the 
University of Hong Kong Committee on the Use of 
Live Animals in Teaching and Research (CULATR 
NO: 3755-15). For high fat diet-induced obese model, 
male C57BL/6N mice (age, 3-4 weeks; body weight, 
11-13g) were fed on 60 kcal% HFD (Research Diets, 
Inc, New Brunswick, NJ, USA) for 12 weeks. Control 
mice were maintained on chow diet (13.5% from fat 
calories) (Lab Diet, Inc, St. Louis, MO, USA). Animals 
were housed under 12 h of light and 12 h dark cycle 
with free access to food and water at the Laboratory 
Animal Unit, University of Hong Kong. Celastrol were 
freshly prepared every day by dissolving the drug 
powder in saline containing 5% DMSO and 1% Tween-
20. For drug treatment, celastrol was administrated to 
mice at the dose of 5 mg/kg/d or 7.5 mg/kg/d via oral 
gavage for consecutive 21 days. The mice in Control 
group and HFD group received the same volume of 
saline containing 5% DMSO and 1% Tween-20 by oral 
gavage. Body weights of mice were monitored on a 
daily basis.  
 
NMR determination of fat mass  
 
Animal body fat composition was assessed using a 
benchtop Bruker minispec LF90 TD-NMR analyzer 
(Bruker Optics, Inc, Billerica, MA, USA) after celastrol 
treatment for 21 days essentially as previously 
described [19]. In brief, the minispec instrument was 
firstly calibrated daily using Bruker standards. Mice 
were weighted and then placed into the instrument for 
non-invasive examination.  
 
Assays of glucose tolerance test and insulin tolerance 
test  
 
Blood glucose levels were measured by collecting blood 
from mice tail vein for assaying glucose tolerance and 
www.aging‐us.com  2079  AGING 
insulin sensitivity as described [19]. ipGTT was 
conducted in mice after 16 hours of fasting (18:00 p.m.-
10:00a.m.). The mice were initially injected D-glucose 
at the dose of 1 g/kg. Blood was collected from mouse 
tail vein at 0, 15, 30, 60, 90, 120 min and measured for 
blood glucose levels using glucose test paper. On the 
other hand, ITT was conducted in mice after 6 hours of 
starvation (10:00 a.m.-16:00 p.m.). The mice were 
initially injected insulin at the dose of 0.75 IU/kg. 
Blood glucose levels were measured in the same 
manner as for ipGTT. 
 
Cell culture  
 
Murine macrophage cell line RAW264.7 was obtained 
from the American Type Culture Collection (Manassas, 
VA, USA). The cells were cultured in DMEM 
supplemented with 10%  FBS,  and  1%  penicillin/strep- 
tomycin (Invitrogen, CA, USA) at 37 oC in a humidified 
incubator containing 5% CO2. For drug treatment, the 
cells were treated with indicated drugs as previously 
described [35].  
 
Measurement of cell viability 
 
The cell viability was evaluated by a standard 
colorimetric assay using 3-[4, 5-dimethylthiazol-2-yl]-2, 
5-diphenyltetrazolium bromide (MTT) as previously 
described [36]. In brief, the cells were treated with 
celastrol at the indicated concentrations for 48 h, and 
subsequently incubated with 0.5 mg/ml MTT in 
phosphate-buffered saline (PBS) for 4 h. Formazan pro-
duction was determined by measuring the absorbance at 
570 nm on a Bio-Rad microplate reader (Hercules, CA, 
USA). The cell viability was presented as a percentage 
relative to vehicle-treated controls.    
 
Quantitative real-time PCR determination of mRNA 
expression 
 
The expression of biomarker mRNAs was determined 
by quantitative real-time PCR technique as described 
[37]. Briefly, total RNAs were isolated from the freshly 
collected livers and epididymal adipose tissues using 
TRIzol reagent (Invitrogen, CA, USA), and converted to 
the corresponding cDNAs using RevertAid first-strand 
cDNA synthesis kit (Thermo Fisher, Waltham, MA, 
USA). Quantitative real time-PCR was performed with 
specific primers from QIAGEN (Valencia, CA, USA) 
and detection reagent SYBR Green mix (QIAGEN, 
Valencia, CA, USA). The primers were obtained from 
QIAGEN and their assay numbers were as follows:  
 
IL-6 (Mm_ll6_1_SG; QT00098875), Il-1β 
(Mm_ll1b_2_SG; QT01048355), iNOS 
(Mm_Nos2_1_SG; QT00100275), TNF-α 
(Mm_Tnf_1_SG; QT00104006), Arg-1 
(Mm_Arg1_1_SG; QT00134288), IL-10 
(Mm_ll10ra_1_SG; QT00112742), CCL-2 
(Mm_Ccl2_1_SG; QT00167832), CXCL10 
(Mm_Cxcl10_1_SG; QT00093436), GAPDH 
(Mm_Gapdh_3_SG; QT01658692). Gene-specific PCR 
products were subjected to melting curve analysis and 
quantified by the 2-ΔΔCt method whereas GAPDH 




The plasma levels of IL-6, TNF-α and IL-1β were 
measured by commercial ELISA kits (i.e., ab222503, 
ab208348 and ab100704) from Abcam (Cambridge, UK) 
according to the manufacturer’s instructions. Mouse 
plasma was isolated from mouse blood in heparinized 
tubes by centrifuging at 3000 × g for 15 min at 4°C. The 
plasma samples were stored at -80°C before use.  
 
Extraction of total protein, nuclear and cytosolic 
protein 
 
The total cellular, cytoplasmic and nuclear proteins 
were prepared as previously described [38]. After drug 
treatment, the cells were lysed in RIPA buffer (Sigma-
Aldrich, St. Louis, MO, USA) with 1% (v/v) protease 
inhibitor cocktail for 30 min on ice. The cell lysates 
were centrifuged at 13000g for 15 min at 4°C. The 
supernatants were collected as the total cellular proteins. 
For the preparation of nuclear and cytosolic proteins, 
cells were washed and lysed with hypotonic buffer (20 
mM Hepes (pH 8.0), 10 mM KCl, 1 mM EDTA, 1.5 
mM MgCl2, 1 mM DTT, 1 mM Na3VO4, 1 mM NaF, 1 
mM PMSF and 1% (v/v) protease inhibitor cocktail) on 
ice for 30 min. After adding 0.625% NP-40, cell lysates 
were centrifuged at 13000g for 15 min. The 
supernatants were collected as the cytosolic proteins, 
whereas the nuclear pellets were re-suspended in cold 
buffer (20 mM Hepes (pH 8.0), 1 mM EDTA, 1.5 mM 
MgCl2, 10 mM KCl, 1 mM DTT, 1 mM Na3VO4, 1 mM 
NaF, 1 mM PMSF, 1% (v/v) protease inhibitor cocktail 
and 20% (v/v) glycerol) for another 30 min. After 
centrifugation at 15000g for 5 min, the supernatants 
were collected as the nuclear extract. Protein 
concentration was determined using a Bio-Rad protein 
assay kit (Hercules, CA, USA).  
 
Western blot analysis 
 
The protein levels of specific biomarkers were analyzed 
by Western blot analysis as described [37, 39]. In brief, 
thirty micrograms of the protein samples were resolved 
by 10% SDS-polyacrylamide gel electrophoresis and 
subsequently transferred to polyvinylidene difluoride 
(PVDF) membrane. Following 1-hour incubation in 5% 
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non-fat milk powder or bovine serum albumin (BSA), 
the membranes were probed with primary antibodies 
against specific biomarkers overnight. The bound 
antibodies were detected with a goat anti-rabbit IgG-
HRP conjugate. The blots were visualized by enhanced 
chemiluminescence (ECL) detection reagents from GE 
Healthcare (Uppsala, Sweden) under a Bio-Rad GelDoc 
imaging system (Hercules, CA, USA). The gel images 





The expression of specific biomarkers in mouse livers 
and epididymal adipose tissues was examined by 
immunofluorescence staining as previously described 
[39, 40]. Briefly, after drug treatment for 21 days, mice 
were sacrificed. Livers and epididymal adipose tissues 
were collected and fixed in 10% formalin in phosphate 
buffer at room temperature for at least 72 h. The fixed 
tissues were sequentially dehydrated with ethanol and 
xylene, embedded in paraffin and dissected into 5 μm 
tissue sections. For immunofluorescence detection, 
tissue sections were firstly revitalized in retrieval buffer 
(PH 6.0), permeabilized with 0.5% Triton X-100 for 30 
min, and blocked with 5% normal goat serum in PBS 
for 2 h at room temperature. Section slides were then 
probed with specific primary antibodies overnight at 
4°C, and subsequently detected by the secondary 
antibodies (i.e., Alexa Fluor 594-conjugated goat anti-
rabbit IgG secondary antibody and Alexa Fluor 488-
conjugated goat anti-mouse IgG secondary antibody) 
for 2 h at room temperature. The cell nuclei were 
stained with DAPI. After the removal of excessive 
fluorescence reagents, the liver and adipose tissues were 
imaged on a Zeiss LSM 780 confocal microscopy (Carl-




The results were presented as mean ± SEM for the 
measurement of body weight and mean ± SD for the 
rest experiments. The differences between two groups 
were analyzed by one-way analysis of variance 
(ANOVA) with post hoc Dunnett’s test using GraphPad 
Prism software (La Jolla, CA, USA). The p-values less 
than 0.05 were considered as significantly different.  
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